The most recent statement that the State of New Jersey Common Pension Fund D has filed with the Securities and Exchange Commission indicates that the fund increased the percentage of Integra LifeSciences Holdings Co. (NASDAQ: IART) shares that it owned by 26.3% during the third quarter (SEC). As a result of the fund’s purchase of an additional 10,156 shares of the life sciences company’s stock during the quarter, the fund’s total number of shares of the company’s stock now stands at 48,810. Around 0.06% of Integra LifeSciences was owned by the State of New Jersey Common Pension Fund D at the end of the most recent quarter. The total value of this holding was $2,068,000.
Several well-known investors have recently made modifications to the number of shares of the company’s stock they own. During the third quarter of 2018, Wipfli Financial Advisors LLC made a brand new investment in Integra LifeSciences for $29,000. A new investment of approximately 54,000 dollars was made in Integra Lifesciences during the second quarter by First Horizon Advisors, Inc. Because of the company’s unwavering dedication to the other business; this investment was made possible. Aubrey Capital Management Ltd. spent $76,000 to acquire a position in Integra Lifesciences during the second quarter of the current fiscal year. During the first three months of the year, Covestor Ltd. increased the percentage of Integra Lifesciences stock owned by 63.0%. Covestor Ltd. now has 1,558 stock issued by the health sciences company, worth $100,000 after purchasing an additional 602 shares during the most recent quarter. This brings the total number of shares owned by Covestor Ltd. And finally, during the first three months of this year, Captrust Financial Advisors increased the amount of Integra Lifesciences stock that is owned by 95.0%, bringing its total percentage of ownership to 100%. Captrust Financial Advisors now owns a total of 2,003 shares with a value of $129,000 after purchasing an additional 976 shares in the life sciences company during the most recent quarter. This brings the total number of shares directly owned by Captrust Financial Advisors to 2,003. At the moment, institutions own 87.60% of the common stock issued by the company.
Several research analysts have just recently released reports on the IART stock that was recently released to the public. On Wednesday, October 12, StockNews.com released a research report on the company’s current standing, which marked the beginning of the website’s coverage of shares of Integra LifeSciences. They suggested to the investors that the best action would be to “buy” the shares. In a research report that was made public by TheStreet on Tuesday, December 27, the brokerage firm rated the stock of Integra LifeSciences higher, moving it from a “c+” rating to a “b-” rating. This move was made because the brokerage firm believes the company will perform better. In a research note published on Thursday, October 27, JMP Securities downgraded their “market outperformed” rating on Integra Lifesciences shares and dropped their price objective from $85.00 to $75.00. Both of these moves were made about the stock’s price. Citigroup raised their price target on shares of Integra Lifesciences from $50.00 to $60.00 and upgraded the stock from a “neutral” rating to an “overweight” rating in a research note published on Monday, December 12. In the end, in a research note published on Tuesday, December 20, Trust Financial raised its price target on Integra Lifesciences shares from $52.00 to $58.00 and classified the company as a “hold.” The stock has received an average recommendation of two buy ratings and four hold ratings from the research analysts. The average rating for this company is “Hold,” and the stock’s consensus target price is currently $58.33. Bloomberg was the source of the information that we gathered.
CART (NASDAQ: IART) was first available for trading on Thursday with a starting price of $54.78. The price-to-earnings ratio for the company is 26.59; the price-to-earnings-to-growth ratio is 1.61; and the beta value is 1.14. The company has a market capitalization of $4.58 billion at present. The current share price of the company’s stock is $55.56, which is higher than its 200-day moving average price of $51.65 per share. During the last 52 weeks, the price of a share of Integra LifeSciences Holdings Co. has ranged from a low of $40.67 to a high of $69.61. The ratio of the current ratio to the quick ratio is 2.91, while the ratio of the current ratio to the quick ratio is 3.93. The ratio of debt to equity is 0.86.
The most recent earnings report for Integra LifeSciences, publicly traded and whose stock is represented on the NASDAQ by the symbol IART, was released on October 26. The life sciences company reported earnings per share for the quarter of $0.86, which is $0.14 higher than the average expectation of $0.72. The company’s revenue for the quarter was also $0.86 million. The company’s sales for the quarter came in at $385.19 million, which is significantly higher than the industry experts’ forecast of $377.79 million, released on October 26. The life sciences company reported earnings per share for the quarter of $0.86, which is $0.14 higher than the average expectation of $0.72. The company’s revenue for the quarter was also $0.86 million. The company’s sales for the quarter came in at $385.19 million, which is significantly higher than the industry experts’ forecast of $377.79 million. Integra Lifesciences had a return on equity of 16.41% and a net margin of 11.05%. Both of these figures are percentages. Sell-side analysts anticipate that Integra Lifesciences Holdings Co. will generate earnings of $3.33 per share in 2018, and this projection is based on the company’s current performance.
Integra LifeSciences Holdings Corporation designs, manufacture, and distributes surgical implants and equipment for general surgery, reconstructive surgery of the extremities, and neurosurgery. They do this to treat patients who require these procedures. Surgeons in every region of the world can carry out these procedures. Codman Specialty Surgical and Tissue Technologies comprise one of the company’s divisions. The company offers neurosurgical and neurocritical care equipment, including, among other things, devices for tissue ablation, dural repair, managing cerebral spinal fluid, intracranial monitoring, and cranial stabilization. Additionally, the company offers devices for monitoring and stabilizing the cranium. In addition, it offers support and after-market services, as well as software for asset management and management of support services.